Edap TMSFOCL +1.91%53 Days Payable is 114.48 as of Mar. 2026, which is 19% above its 10-year median of 95.89. GuruFocus rates FOCL with a GF Score™ of 53/100 and a GF Value™ of $4.52 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 117 Medical Distribution companies, Edap TMS ranks worse than 54.7% on this metric.
Edap TMS's average Accounts Payable for the
three
months ended in Mar. 2026 was $12.1 Mil. Edap TMS's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $9.7 Mil.
Hence, Edap TMS's Days Payable for the
three
months ended in Mar. 2026 was 114.48.
The historical rank and industry rank for Edap TMS's Days Payable or its related term are showing as below:
FOCL'
s Days Payable Range Over the Past 10 Years
Min: 73.55 Med: 95.89 Max: 114.32
Current: 74.4
During the past 13 years, Edap TMS's highest Days Payable was 114.32. The lowest was 73.55. And the median was 95.89.
FOCL's Days Payable is ranked worse than 54.7% of 117
companies
in the Medical Distribution industry
Industry Median: 79.11
vs FOCL: 74.40
Edap TMS's Days Payable
declined
from Mar. 2025 (143.85) to Mar. 2026 (114.48).
It may suggest that Edap TMSaccelerated paying its suppliers.
Edap TMS Days Payable Related Terms
Edap TMS Days Payable Historical Data
* Premium members only.
The historical data trend for Edap TMS's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Edap TMS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edap TMS Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Edap TMS's Days Payable distribution charts can be found below:
* The bar in red indicates where Edap TMS's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Edap TMS's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edap TMS (FOCL) has a Days Payable of 114.48 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Edap TMS and its competitors. This is 19% above median its historical median of 95.89. Over the past decade, Edap TMS's Days Payable has ranged from 73.55 to 114.32. According to the industry distribution chart, Edap TMS ranks #64 out of 117 companies in the Medical Distribution industry, placing it in the top 54.7%.
Is Edap TMS's Days Payable too high?
Edap TMS's current Days Payable of 114.48 is 19% above median its 10-year median of 95.89. Over the past 10 years, this metric has ranged from a low of 73.55 to a high of 114.32. The Medical Distribution industry median Days Payable is 79.11. Edap TMS's value of 114.48 is 44.7% above this industry median. Based on the distribution chart, Edap TMS ranks #64 out of 117 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Edap TMS has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Edap TMS's Days Payable compare to ACH and YI?
According to the Medical Distribution industry distribution chart, Edap TMS ranks #64 out of 117 companies for Days Payable. This places Edap TMS in the lower half of its industry. The industry median Days Payable is 79.11. Edap TMS's value of 114.48 is 44.7% above this benchmark. Historically, Edap TMS's own Days Payable has ranged from 73.55 to 114.32 over the past decade. While the company's 10-year median is 95.89 vs. the industry median of 79.11, Edap TMS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 79.11, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edap TMS's current Days Payable of 114.48 is 44.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Edap TMS and its competitors. For the Medical Distribution industry, the median Days Payable is 79.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edap TMS's current Days Payable is 114.48, which is 19% above median its own 10-year median of 95.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edap TMS stock overvalued right now?
Based on GuruFocus' analysis, Edap TMS (FOCL) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.52, compared to a current price of $5.08 — trading 12.3% above its estimated fair value. The current Days Payable is 114.48, which is 19% above median its 10-year median of 95.89 and 44.7% above the Medical Distribution industry median of 79.11. Edap TMS's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Edap TMS (FOCL), the current Days Payable is 114.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edap TMS (FOCL) Overvalued in 2026?
Based on GuruFocus' analysis, Edap TMS stock appears to be overvalued.
The current stock price of $5.08 is trading 12.3% above its estimated GF Value™ of $4.52.
GuruFocus considers Edap TMS to be Modestly Overvalued.
Key valuation signals for FOCL:
Days Payable: 114.48 (19% above median its 10-year median of 95.89)
GF Value™: $4.52 vs. price of $5.08 (12.3% above fair value)
Industry Position: 44.7% above the Medical Distribution median (#64 of 117)
No single metric tells the full story. See the FOCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
53GF Score
Get the complete analysis for FOCL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FOCL has been successfully added to your 
